Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pCDNA5-Frt-Fucci2a (#RDB16056)

Flp/In targeting construct of Fucci2a

Clone info. Flp/In targeting construct to make a single insertion into Flp/In compatible cell lines of Fucci2a a multicistronic version of Fucci2 composed of mVenus-hGem(1/110) and mCherry-hCdt1(30/120) fused with t2a.
Comment This clone was used in generating stable cell lines by the depositor.
Vector backbone pCDNA5/Frt (Plasmid)
Size of vector backbone 5.0 kb
Selectable markers Ampicillin (E. coli), Hygromycin (mammalian cells)
Gene/insert name Human CDT1 cDNA Human Gem cDNA Discosoma sp. RFP cDNA Aequorea victoria GFP cDNA
Depositor|Developer Jackson, Ian | Mort, Richard |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution 1) The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for publication of research papers and the BIOLOGICAL RESOURCE may not be used on humans.
2) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the literature designated by the DEPOSITOR (Mort, R.L. et al., Cell Cycle 13 (17): 2681-2696, (2014)) is requested.
3) In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR and Dr. Richard Mort of Lancaster University is requested.
4) The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
5) The BIOLOGICAL RESOURCE may not be used for commercial purposes by the RECIPIENT.
6) The RECIPIENT may not transfer the BIOLOGICAL RESOURCE to any third parties.
Additional terms and conditions:
1. If the BIOLOGICAL RESOURCE is to be used by a for-profit organization, the RECIPIENT must agree with RIKEN Innovation Co., Ltd. on the terms and conditions of its use. For inquiries, please contact:
license-contact@innovation-riken.jp
2. The RECIPIENT's Scientist agrees not to transfer the BIOLOGICAL RESOURCE and its derivatives to any third party including any resource center without the prior written consent of Dr. Atsushi Miyawaki.
Remarks
This RESOURCE contains a fluorescent protein provided by Prof. Roger Tsien. UCSD's MTA is also required. Please visit Additional Forms section. This RESOURCE is not provided to for-profit organization or for for-profit research by non-profit organizations.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 1) The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for publication of research papers and the BIOLOGICAL RESOURCE may not be used on humans.
2) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the literature designated by the DEPOSITOR (Mort, R.L. et al., Cell Cycle 13 (17): 2681-2696, (2014)) is requested.
3) In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR and Dr. Richard Mort of Lancaster University is requested.
4) The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
5) The BIOLOGICAL RESOURCE may not be used for commercial purposes by the RECIPIENT.
6) The RECIPIENT may not transfer the BIOLOGICAL RESOURCE to any third parties.
付加的使用条件:
1. If the BIOLOGICAL RESOURCE is to be used by a for-profit organization, the RECIPIENT must agree with RIKEN Innovation Co., Ltd. on the terms and conditions of its use. For inquiries, please contact:
license-contact@innovation-riken.jp
2. The RECIPIENT's Scientist agrees not to transfer the BIOLOGICAL RESOURCE and its derivatives to any third party including any resource center without the prior written consent of Dr. Atsushi Miyawaki.
備考 提供条件は英文のまま記載してください。
Prof. Roger Tsienから供与された蛍光タンパク質を含みます。UCSDとのMTA締結が必要です。「申込みに必要な書式」をご覧ください。本件リソースは営利機関および非営利機関による営利目的研究には提供いたしません。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB16056 pCDNA5-Frt-Fucci2a DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pCDNA5-Frt-Fucci2a was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB16056).

Reference section:

Mort, R.L., Ford, M.J., Sakaue-Sawano, A., Lindstrom, N.O., Casadio, A., Douglas, A.T., Keighren, M.A., Hohenstein, P., Miyawaki, A., Jackson, I.J., Fucci2a: a bicistronic cell cycle reporter that allows Cre mediated tissue specific expression in mice. Cell Cycle 13 (17): 2681-2696 (2014). PMID 25486356. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)


QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB16056_A9K8p1-1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: CMV_Forward (Pr0016)
Region: CMV pro, T7 pro, insert 5' (mCherry)
Sequence file: RDB16056_A9K8a.seq check
>D05769A1_A9K8_1_CMV_Forward_A06_03_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNGCNAATGG GCGGTANGCG TGTACGGTGG GNGGTCTATA
   61 TAAGCAGAGC TCTCTGGCTA ACTAGAGAAC CCACTGCTTA CTGGCTTATC GAAATTAATA
  121 CGACTCACTA TAGGGAGACC CAAGCTGGCT AGAATTCCTC GACACGCGTA TGGTGAGCAA
  181 GGGCGAGGAG GATAACATGG CCATCATCAA GGAGTTCATG CGCTTCAAGG TGCACATGGA
  241 GGGCTCCGTG AACGGCCACG AGTTCGAGAT CGAGGGCGAG GGCGAGGGCC GCCCCTACGA
  301 GGGCACCCAG ACCGCCAAGC TGAAGGTGAC CAAGGGTGGC CCCCTGCCCT TCGCCTGGGA
  361 CATCCTGTCC CCTCAGTTCA TGTACGGCTC CAAGGCCTAC GTGAAGCACC CCGCCGACAT
  421 CCCCGACTAC TTGAAGCTGT CCTTCCCCGA GGGCTTCAAG TGGGAGCGCG TGATGAACTT
  481 CGAGGACGGC GGCGTGGTGA CCGTGACCCA GGACTCCTCC CTGCAGGACG GCGAGTTCAT
  541 CTACAAGGTG AAGCTGCGCG GCACCAACTT CCCCTCCGAC GGCCCCGTAA TGCAGAAGAA
  601 GACCATGGGC TGGGAGGCCT CCTCCGAGCG GATGTACCCC GAGGACGGCG CCCTGAAGGG
  661 CGAGATCAAG CAGAGGCTGA AGCTGAANGA CGGCGGCCAC TACGACGCTG ANGTCAAGAC
  721 CACCTACAAN GCCAAGAAGC CCGTGCAGCT GCCCGGCGCC TACAACGTCA ACATCAAGTT
  781 GGACATCACC TCCCACAACG AGGNNTACAC CATCNNNGAA CAGTACGAAC GCGCCGANGG
  841 CCGCNACTCC ACCGGCGGCA TGNNCGANCT GTACAAGGGN TATNCNTCAC ACNNGCGGNC
  901 GCNCNNNCCN AGCCCCCGCC NGGNCNGCNC TNCNNNNCCC GGNCNTNNGN NANNNNNNNN
961 NN
//
Primer: BGH_rev2 (Pr0606)
Region: BGH p(A), insert 3' (Gem1_1-110, mVenus)
Sequence file: RDB16056_A9K8b.seq check
>D05769A1_A9K8_1_BGH_rev2_B06_06_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNG GNNGNNGGGC AAACAACAGN TGGCTGGCAA CTAGAAGGCA
   61 CAGTCGAGGC TGATCAGCGG GTTTAAACGG CCCGGCGCGC CACATGTGGT ACCTTACAGC
  121 GCCTTTCTCC GTTTTTCTGC CACTTCCTTC CAATACTGAG AGGATGGATT TTCTTTAATC
  181 ATAAGATCAA ATGACTCCTG GGTGACTCCT CCAAGATTTT TATTTTCACT AGATTCTGGG
  241 ACAATAACCC CAGGGCTGGA AGTTGTAGAT GTTAAGTGGT CATTCCGATG TTTCCTTTTG
  301 GACAAGCCTG CGGACAGCTC ATTTTCTCTT CCAACAAGAG ATCCAGATGC AGAAGGCTGA
  361 ATCATCTTCA GAGTTCTTCT TGGGACAGAA CTATTCTTTA TATTCTCTTT GATTTCTTCT
  421 TGTTTCTGCT TCATACTGGG ATTCATCTCG AGCGGCCGCC AGTGTGATGG ATATCCCTTG
  481 TACAGCTCGT CCATGCCGAG AGTGATCCCG GCGGCGGTCA CGAACTCCAG CAGGACCATG
  541 TGATCGCGCT TCTCGTTGGG GTCTTTGCTC AGCTTGGACT GGTAGCTCAG GTAGTGGTTG
  601 TCGGGCAGCA GCACGGGGCC GTCGCCGATG GGGGTGTTCT GCTGGTAGTG GTCGGCGAGC
  661 TGCACGCCGC CGTCCTCGAT GTTGTGGCGG ATCTTGAAGT TGGCCTTGAT GCCGTTCTTC
  721 TGCTTGTCGG CGGTGATATA GACGTTGTGG CTGTTGTAGT TGTACTCCAG CTTGTGCCCC
  781 AGGATGTTGC CGTCCTCCTT GAAGTCGATG CCCTTCAGCT CGATGCGGTT CACCAGGGNG
  841 TCGCCCTCNA NCTTCACCTC NGCGCGGGNC TNNTANTTGC CGNCNNNCTT GAAGAANANG
  901 GNGCGNNNCN GGACGTANCC TTCGGGNNTG GNNGNNTNNN NNNNNNCNNG CNNNTTNNNN
961 NNNNNN
//
Primer: HygR-M_R (Pr0769)
Region: HygR, FRT
Sequence file: RDB16056_A9K8c.seq check
>D05769A1_A9K8_1_HygR-M_R_A02_01_ABI08.ab1
    1 NNNNNNNNNN NNNNNNNNNN GNNCGANTCC TTGCGGTCCG AATGGGCCGA ACCCGCTCGT
   61 CTGGCTAAGA TCGGCCGCAG CGATCGCATC CATGGCCTCC GCGACCGGCT GCAGAACAGC
  121 GGGCAGTTCG GTTTCAGGCA GGTCTTGCAA CGTGACACCC TGTGCACGGC GGGAGATGCA
  181 ATAGGTCAGG CTCTCGCTGA ATTCCCCAAT GTCAAGCACT TCCGGAATCG GGAGCGCGGC
  241 CGATGCAAAG TGCCGATAAA CATAACGATC TTTGTAGAAA CCATCGGCGC AGCTATTTAC
  301 CCGCAGGACA TATCCACGCC CTCCTACATC GAAGCTGAAA GCACGAGATT CTTCGCCCTC
  361 CGAGAGCTGC ATCAGGTCGG AGACGCTGTC GAACTTTTCG ATCAGAAACT TCTCGACAGA
  421 CGTCGCGGTG AGTTCAGGCT TTTTGGCCAA GGAAGTTCCT ATACTTTCTA GAGAATAGGA
  481 ACTTCGGAAT AGGAACTTCT AGGTACGTGA ACCATCACCC TAATCAAGTT TTTTGGGGTC
  541 GAGGTGCCGT AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCGATTTA GAGCTTGACG
  601 GGGAAAGCCG GCGAACGTGG CGAGAAAGGA AGGGAAGAAA GCGAAAGGAG CGGGCGCTAG
  661 GGCGCTGGCA AGTGTAGCGG TCACGCTGCG CGTAACCACC ACACCCGCCG CGCTTAATGC
  721 GCCGCTACAG GGCGCGTGGG GANACCCCCT AGAGCCCCAG CTGGTTCTTT CCGCCTCANA
  781 AGCCATAGAG CCCACCGCAT CCCCAGCATG CCTGCTATTG TCTTCCCNAT CCTCCCCCTT
  841 GCTGTCCTGC CCCACCCCNC CCCCCCAGAA TANAATGANA CCTACTCNGA NAATGCGATG
  901 CAATTTCCTC ATTTTATTAN GAAAGGANAG NGGGANTGGN ACCNNCCANG GNNNNNGNAN
  961 NNNNNNGGGG NAGGGNNAAN NNNNNNANGG NNNGNNNCTA NNANNNNCAG NCNNNNNNNN
1021 NN
//
Primer: mCherry-M_F1 (Pr0767)
Region: insert mid (mCherry, Cdt1_30-120)
Sequence file: RDB16056_A9K8d.seq check
>D05769A1_A9K8_1_mCherry-M_F1_A06_03_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NGNNGAANAN NNCNTGGGCT GGGNNGCCTC CTCCGAGCGG
   61 ANGTACCCCG ANGNNGGCGC CCTGAAGGGC GAGATCAAGC AGAGGCTGAA GCTGAAGGAC
  121 GGCGGCCACT ACGACGCTGA GGTCAAGACC ACCTACAAGG CCAAGAAGCC CGTGCAGCTG
  181 CCCGGCGCCT ACAACGTCAA CATCAAGTTG GACATCACCT CCCACAACGA GGACTACACC
  241 ATCGTGGAAC AGTACGAACG CGCCGAGGGC CGCCACTCCA CCGGCGGCAT GGACGAGCTG
  301 TACAAGGGAT ATCCATCACA CTGGCGGCCG CTCGAGCCCA GCCCCGCCAG GCCCGCACTC
  361 CGCGCCCCGG CCTCCGCTAC CAGTGGCAGC CGCAAGCGCG CCCGCCCGCC CGCCGCCCCC
  421 GGACGCGACC AGGCCAGGCC ACCGGCCCGC AGGAGACTGC GGCTGTCGGT GGACGAGGTT
  481 TCCAGCCCCA GTACCCCCGA GGCCCCAGAC ATCCCAGCCT GCCCTTCTCC GGGCCAGAAG
  541 ATAAAGAAAT CCACCCCGGC AGCAGGTCAG CCGCCCCACC TGACATCCGC GCAGGACCAG
  601 GACACCATCC AATTGGAAGG CCGTGGCTCT CTTCTCACTT GTGGCGATGT CGAAGAGAAT
  661 CCTGGACCCA TGGTGAGCAA GGGCGAGGAG CTGTTCACCG GGGTGGTGCC CATCCTGGTC
  721 GAGCTGGACG GCGACGTAAA CGGCCACAAG TTCAGCGTGT CCGGCGAGGG CGANGGCGAN
  781 GCCACCTACN GCAAGCTGAN CCTGAANCTG ATCTGCACCA CCGGCAAGCT GCCCGNGCCC
  841 TGGCCCACCC TCNNGANCAC NCNNGGCTAC NGNCNGCAGN GNNNCNCCCG CNACCCCGAN
  901 CACNTGAAGC AGCACGANNN CTNCANGNNC GCCNTGCCCN NANNNNTANN NNCNNGNANC
961 GNANCATCNN NTNNNNNGNA NNNNNNNNNN
//
Primer: Cdt1_F1 (Pr0768)
Region: insert mid (T2A, mVenus)
Sequence file: RDB16056_A9K8e.seq check
>D05769A1_A9K8_1_Cdt1_F1_E06_15_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNCNN ANGNNNNGGN NNNCNTCNAA TTGGAAGGCC GTGGCTCTCT
   61 TCTCNCTTGT GGCGATGTCG AAGAGAATCC TGGACCCATG GTGAGCAAGG GCGAGGAGCT
  121 GTTCACCGGG GTGGTGCCCA TCCTGGTCGA GCTGGACGGC GACGTAAACG GCCACAAGTT
  181 CAGCGTGTCC GGCGAGGGCG AGGGCGATGC CACCTACGGC AAGCTGACCC TGAAGCTGAT
  241 CTGCACCACC GGCAAGCTGC CCGTGCCCTG GCCCACCCTC GTGACCACCC TGGGCTACGG
  301 CCTGCAGTGC TTCGCCCGCT ACCCCGACCA CATGAAGCAG CACGACTTCT TCAAGTCCGC
  361 CATGCCCGAA GGCTACGTCC AGGAGCGCAC CATCTTCTTC AAGGACGACG GCAACTACAA
  421 GACCCGCGCC GAGGTGAAGT TCGAGGGCGA CACCCTGGTG AACCGCATCG AGCTGAAGGG
  481 CATCGACTTC AAGGAGGACG GCAACATCCT GGGGCACAAG CTGGAGTACA ACTACAACAG
  541 CCACAACGTC TATATCACCG CCGACAAGCA GAAGAACGGC ATCAAGGCCA ACTTCAAGAT
  601 CCGCCACAAC ATCGAGGACG GCGGCGTGCA GCTCGCCGAC CACTACCAGC AGAACACCCC
  661 CATCGGCGAC GGCCCCGTGC TGCTGCCCGA CAACCACTAC CTGAGCTACC AGTCCAAGCT
  721 GANCAAAGAC CCCAACGAGA AGCGCGATCA CATGGTCCTG CTGGAGTTCG TGACCGCCGC
  781 CNGGATCACT CTCGGCATGG NCGANCTGTA CAANGGATAT CCATCACACT NNCGGCCGCT
  841 CNANATGAAT CCCANTATGA AGCANAANNC AAGAAGAAAT CAAAGAGAAT ATAAAGAATA
901 NTTCNGNCCC NAGAANAANN NNNNANNANN ANTCANCCNN NNNNNNNN
//

Please visit Sequencing and PCR primers for primer information.


References

Original, user report and related articles

original Mort, R.L., Fucci2a: a bicistronic cell cycle reporter that allows Cre mediated tissue specific expression in mice. Cell Cycle 13 (17): 2681-2696 (2014). PMID 25486356. [link to RRC of NBRP]